DCF Advisers LLC Buys Shares of 30,500 Zimmer Biomet Holdings, Inc. $ZBH

DCF Advisers LLC bought a new position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the 2nd quarter, HoldingsChannel.com reports. The fund bought 30,500 shares of the medical equipment provider’s stock, valued at approximately $2,626,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in ZBH. BlackRock Inc. acquired a new stake in shares of Zimmer Biomet during the 2nd quarter valued at about $1,344,282,000. M&T Bank Corp increased its holdings in Zimmer Biomet by 15,705.6% in the fourth quarter. M&T Bank Corp now owns 3,571,595 shares of the medical equipment provider’s stock worth $321,158,000 after buying an additional 3,548,998 shares during the last quarter. Norges Bank acquired a new position in Zimmer Biomet in the fourth quarter worth approximately $221,234,000. Franklin Resources Inc. raised its position in Zimmer Biomet by 43.2% during the fourth quarter. Franklin Resources Inc. now owns 6,685,987 shares of the medical equipment provider’s stock valued at $601,204,000 after acquiring an additional 2,017,857 shares in the last quarter. Finally, Auto Owners Insurance Co raised its position in Zimmer Biomet by 8,892.0% during the fourth quarter. Auto Owners Insurance Co now owns 2,009,712 shares of the medical equipment provider’s stock valued at $180,713,000 after acquiring an additional 1,987,362 shares in the last quarter. 88.89% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have commented on ZBH shares. Sanford C. Bernstein boosted their target price on shares of Zimmer Biomet from $91.00 to $93.00 and gave the stock a “market perform” rating in a research report on Thursday, August 6th. Truist Financial raised their price target on shares of Zimmer Biomet from $92.00 to $106.00 and gave the company a “hold” rating in a report on Thursday, August 6th. Zacks Research lowered shares of Zimmer Biomet from a “hold” rating to a “strong sell” rating in a research note on Monday, July 27th. Canaccord Genuity Group upped their price objective on shares of Zimmer Biomet from $83.00 to $100.00 and gave the stock a “hold” rating in a report on Monday, August 10th. Finally, Royal Bank Of Canada increased their target price on shares of Zimmer Biomet from $101.00 to $110.00 and gave the stock an “outperform” rating in a research report on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, thirteen have assigned a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $104.42.

Zimmer Biomet Price Performance

Shares of Zimmer Biomet stock opened at $100.65 on Thursday. The company has a current ratio of 1.69, a quick ratio of 0.94 and a debt-to-equity ratio of 0.50. The firm has a fifty day simple moving average of $92.16 and a 200-day simple moving average of $90.85. The stock has a market capitalization of $19.20 billion, a price-to-earnings ratio of 24.49, a PEG ratio of 2.70 and a beta of 0.45. Zimmer Biomet Holdings, Inc. has a 1-year low of $79.12 and a 1-year high of $108.29.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.01 by $0.06. The business had revenue of $2.18 billion for the quarter, compared to analyst estimates of $2.13 billion. Zimmer Biomet had a net margin of 9.48% and a return on equity of 13.12%. Zimmer Biomet’s revenue was up 4.8% compared to the same quarter last year. During the same period last year, the business posted $2.07 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. On average, sell-side analysts expect that Zimmer Biomet Holdings, Inc. will post 8.53 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, July 31st. Shareholders of record on Thursday, June 25th were issued a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date was Thursday, June 25th. Zimmer Biomet’s dividend payout ratio is 23.36%.

Insider Activity

In other news, insider Sang Yi sold 5,000 shares of Zimmer Biomet stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $82.64, for a total value of $413,200.00. Following the transaction, the insider directly owned 27,251 shares in the company, valued at approximately $2,252,022.64. The trade was a 15.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 1.28% of the company’s stock.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.